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Differentiation of Vancomycin-Resistant Enterococcus faecium
and Enterococcus faecalis Isolates
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The development of reliable and rapid methods for the identification of patients colonized with vanco-
mycin-resistant enterococci (VRE) is central to the containment of this agent within a hospital environ-
ment. To this end, we evaluated a prototype chromogenic agar medium (VRE-BMX; bioMe´rieux, Marcy
l’Etoile, France) used to recover VRE from clinical specimens. This medium can also identify isolated
colonies as either vancomycin-resistant Enterococcus faecium or Enterococcus faecalis, based on distinct
colony colors. We compared the performance of VRE-BMX with bile esculin azide agar supplemented with
vancomycin (BEAV). For this study, 147 stool samples were plated on each test medium and examined
after 24 and 48 h of incubation. At 24 h, the sensitivity and specificity of each medium were as follows:
BEAV, 90.9% and 89.9%, respectively; VRE-BMX, 96.4% and 96.6%, respectively. The positive predictive
values (PPV) of VRE-BMX and BEAV at 24 h were 89.8% and 80.7%, respectively. VRE-BMX provided the
identification of 10 isolates of vancomycin-resistant E. faecalis and 4 isolates of vancomycin-resistant E.
faecium that were not recovered by BEAV. Further, VRE-BMX was capable of identifying patients colo-
nized with both E. faecium and E. faecalis, a feature useful for infection control purposes that is not a
function of BEAV. In terms of the recovery of vancomycin-resistant E. faecium and E. faecalis, the
sensitivity and PPV were as follows: BEAV, 75.7% and 74.6%, respectively; VRE-BMX, 95.5% and 91.3%,
respectively. In this initial evaluation, we found that VRE-BMX provided improved recovery of VRE from
stool specimens, with the added advantage of being able to differentiate between vancomycin-resistant E.
faecalis and E. faecium. Extending the incubation period beyond 24 h did not significantly improve the
recovery of VRE and resulted in decreased specificity.
Enterococcus species are members of the normal intestinal
flora and are the most common aerobic gram-positive cocci
found in the large bowel of humans. The organisms have
gained more notoriety, however, as nosocomial pathogens,
now grouped as the third most common cause of bacteremia
in the United States (5). Of the clinically important entero-
cocci, E. faecium is more likely to acquire resistance to
glycopeptides, while E. faecalis is linked more frequently to
serious disease (12). The most common form of glycopep-
tide resistance is mediated by vanA, a transposon-mediated,
inducible gene that leads to high-level resistance to vanco-
mycin and teicoplanin. vanA can be plasmid mediated or
chromosomal (10, 18). Glycopeptide resistance stemming
from vanB is less common and confers resistance to vanco-
mycin at moderate to high levels but not to teicoplanin (6,
12). Less commonly acquired vancomycin resistance genes
include vanD, vanE, vanF, and vanG, which confer moderate
to low-level resistance to glycopeptides.
The clinical impact of infection by vancomycin-resistant en-
terococci (VRE) has been examined in several studies (2, 3, 8,
9, 14–16, 19), with the most notable consequences being in-
creases in mortality, length of hospital stay, and cost of hospi-
talization. While a clear link between colonization with glyco-
peptide-resistant Enterococcus and increased mortality has not
been clearly established (12), antimicrobial therapy does pro-
mote selection and proliferation of VRE in the hospital envi-
ronment (11, 12). Patients who become colonized with VRE
can become asymptomatic carriers for months to years (12).
Until recently, detection of VRE colonization relied on
culture techniques using selective/differential media (17).
To date, the most effective medium identified for screening
for VRE has been bile esculin azide agar supplemented with
6 g of vancomycin/ml (BEAV) (11). While being reason-
ably sensitive, the use of selective culture techniques can be
time consuming (the average recovery and identification
time is 24 to 72 h) and labor intensive. Recent advances in
the use of highly specific chromogenic substrates with suf-
ficient sensitivity to identify VRE in a selective agar medium
led to the development of VRE-BMX. The chromogenic
substrates incorporated in VRE-BMX are targeted by en-
zymes specific for E. faecium or E. faecalis. Enzymatic deg-
radation generates either purple (E. faecium) or blue-green
(E. faecalis) by-products that distinguish the colony pigmen-
tation of each species.
In this study, we compared the performance characteristics
of VRE-BMX to BEAV for the detection and differentiation
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of VRE from stool samples obtained from hospitalized pa-
tients.
MATERIALS AND METHODS
Study enrollment and collection of clinical specimens. Study subjects were
selected from inpatients at Barnes-Jewish Hospital, a 1,442-bed tertiary care
hospital in St. Louis, MO. Patients were considered for inclusion in the study if
fecal specimens were submitted to the Barnes-Jewish microbiology laboratory for
routine VRE screening. Collected specimens were transported and stored at 4°C
for up to 24 h before being cultured. This study was approved by the Washington
University Human Studies Committee (IRB no. 05-1091).
Media and culture conditions. We compared the performance of an experi-
mental chromogenic medium, VRE-BMX (bioMe´rieux, Marcy l’Etoile, France),
with that of BEAV (Remel, Lenexa, KS). VRE-BMX and BEAV plates were
directly inoculated by submerging a sterilized 10-l inoculating loop in the
specimen and streaking for isolation by the quadrant technique. This procedure
was repeated for each medium type. Plates were incubated at 35°C in ambient air
and examined for growth at 24 and 48 h. Colonies on VRE-BMX plates with
purple or green pigmentation were presumptively identified as vancomycin-
resistant E. faecium or E. faecalis, respectively (Fig. 1). The appearance of black
colonies on BEAV plates was presumed to indicate positivity for VRE. Following
observation of the colony morphologies, individual unique colonies were subcul-
tured onto CPS ID 3 medium (bioMe´rieux), a chromogenic medium for pre-
sumptive identification of enterococci. Individual colonies were also subcultured
to tryptic soy agar plates supplemented with 5% sheep blood (Remel) for con-
firmatory identification and antimicrobial susceptibility testing with the VITEK
2 automated identification and susceptibility system (bioMe´rieux). Additionally,
the identification of isolated colonies and glycopeptide resistance were con-
firmed genotypically by PCR or PCR-restriction fragment length polymorphism
(RFLP) analysis.
DNA isolation for PCR analysis. Bacteria were grown overnight at 35°C on
Columbia 5% sheep blood agar plates (bioMe´rieux). A bacterial suspension
equivalent to a 0.5 McFarland standard was prepared, and cells were disrupted
by mechanical lysis with glass beads of different sizes. After vortexing of the
bacterial suspensions with beads for 2 min, samples were placed on ice and the
supernatant was saved for amplification.
Multiplex PCR for detection of glycopeptide resistance genes and identifica-
tion of E. faecium and E. faecalis. Multiplex PCR was adapted from the method
previously described by Depardieu et al. (7). Briefly, the multiplex PCR consisted
of 25 l of 2 reaction mix (QIAGEN Multiplex PCR master mix; QIAGEN,
Courtaboeuf, France), 0.2 M concentrations of each primer, 5 l of 5 Q-
solution (QIAGEN), and 5 l of template DNA in a total volume of 50 l.
Samples were amplified as follows: an initial denaturation step at 95°C for 15
min; 35 cycles of denaturation at 94°C for 30 s, annealing at 54°C for 90 s, and
elongation at 72°C for 1 min; and a final elongation at 72°C for 10 min. Amplified
products were detected and quantified with a 2100 BioAnalyzer system (Agilent,
Massy, France), according to the manufacturer’s instructions.
Identification of enterococci by PCR-RFLP of the sodA gene. A 429-bp frag-
ment internal to the sodA gene was amplified with degenerate primers, as
FIG. 1. VRE-BMX medium plated with E. faecalis and E. faecium. This figure demonstrates the ability of VRE-BMX to identify E.
faecium and E. faecalis based on the color of the colony; on VRE-BMX, colonies of E. faecalis appear blue-green and colonies of E. faecium
appear purple. For the purposes of this study, fecal specimens were plated directly to VRE-BMX and BEAV and observed for growth at
24 and 48 h.
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previously described by Poyart et al. (13). For RFLP analysis, 8 l of PCR
product was digested with 1 l (10 units/l) of MseI endonuclease (New England
BioLabs, Ipswich, MA) in a total volume of 20 l, according to the manufactur-
er’s instructions. Digested products were then visualized by electrophoresis with
a 2100 BioAnalyzer system (Agilent). RFLP patterns were analyzed by compar-
ing the number and size of fragments between enterococcal species.
Statistical analysis. To determine whether the results from each medium were
significantly different, the significance of results was determined by MacNemar’s
test or by binomial distribution with the significance level fixed at 5% (if P was
5%, then the differences in performance were considered statistically signifi-
cant).
RESULTS
Isolation of VRE from fecal samples. Stool samples from 147
patients were cultured for VRE according to the protocol.
Colonies on VRE-BMX were screened for a purple (vanco-
mycin-resistant E. faecium) or blue-green (vancomycin-resis-
tant E. faecalis) hue (Fig. 1). Purple or blue-green colonies
were easily differentiated from other flora. BEAV plates were
screened for colonies causing a blackening of the medium
around the colony and were easily distinguished from sur-
rounding contaminants. Following observation of the colony
morphologies, suspect colonies of VRE were identified and
tested for glycopeptide resistance with VITEK 2 and con-
firmed by molecular techniques, as described in Materials and
Methods.
VRE-BMX performance characteristics. Upon completion
of the medium evaluation, an analysis was performed to de-
termine the sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPV) at 24 and 48 h.
The sensitivity of each medium was calculated for detection of
VRE as well as for the detection of vancomycin-resistant E.
faecium and E. faecalis. After molecular confirmation, the sen-
sitivity of VRE-BMX for the detection of VRE at 24 and 48 h
was 96.4% and 94.8%, respectively (Table 1). The sensitivity of
BEAV for the detection of VRE was 90.9% at 24 h and 91.4%
at 48 h (Table 1). The differences in sensitivity between 24 and
48 h were not statistically significant.
Further, the sensitivity of each medium was analyzed for the
detection of Enterococcus species that carry clinically signifi-
cant glycopeptide resistance determinants (vanA, vanB), most
notably in vancomycin-resistant E. faecium and E. faecalis. The
sensitivity of VRE-BMX for the detection of E. faecium was
94.4% at 24 h, and that of BEAV was 85.7% (Table 2). There
was no significant change in sensitivity when the incubation
period of either medium was extended to 48 h (Table 2). The
sensitivity of VRE-BMX for the detection of E. faecalis colo-
nization was 100% at both 24 and 48 h, while BEAV had a
calculated sensitivity of 16.7 and 13.3% after 24 and 48 h of
incubation, respectively (Table 2). The marked difference in
the sensitivity of BEAV between vancomycin-resistant E. fae-
cium and E. faecalis can be explained because VRE-BMX
identified 11 patients that were colonized with both E. faecium
and E. faecalis. While VRE-BMX can easily distinguish dual
colonization because of the differential properties of the chro-
mogenic substrates, BEAV has no such differential capabili-
ties, making it impossible to differentiate vancomycin-resistant
E. faecium from E. faecalis without further testing.
As with the sensitivity analysis, the specificity of VRE-BMX
compared to BEAV was calculated at 24 and 48 h. The spec-
ificity analysis showed that VRE-BMX was 96.6% and 73.9%
specific at 24 and 48 h, respectively (Table 1). The specificity of
BEAV at 24 h was 89.9%, but it dropped to 77.2% after
extended incubation (Table 1). The drop in specificity of each
medium was due to the proliferation of contaminant flora that
may cause false-positive results. These organisms included
gram-negative bacilli and yeast on VRE-BMX and gram-pos-
itive bacilli, gram-positive cocci, and Enterococcus species
other than E. faecalis or E. faecium on BEAV.
The PPV and NPV of both media are shown in Table 3.
TABLE 1. Sensitivity and specificity analysis of VRE-BMX and











24 VRE-BMX 53 2 96.4 96.6
BEAV 50 5 90.9 89.9
48 VRE-BMX 55 3 94.8 73.9
BEAV 53 5 91.4 77.2
a A true positive (TP) is defined as a blue-green or purple colony on VRE-
BMX or a gray to black colony on BEAV that was identified as VRE by VITEK
2 and confirmed by PCR.
b A false negative (FN) is defined as an isolate that was confirmed as VRE on
one medium but did not grow on another medium.
TABLE 2. Sensitivity analysis of VRE-BMX and BEAV for
E. faecium or E. faecalis at 24 and 48 h
Incubation







24 VRE-BMX E. faecium 51 3 94.4
E. faecalis 12 0 100.0
BEAV E. faecium 48 8 85.7
E. faecalis 2 10 16.7
48 VRE-BMX E. faecium 54 3 94.7
E. faecalis 14 0 100.0
BEAV E. faecium 51 6 89.5
E. faecalis 2 13 13.3
a A true positive (TP) is defined as a blue-green or purple colony on VRE-
BMX or a gray to black colony on BEAV that was identified as VRE by VITEK
2 and confirmed by PCR.
b A false negative (FN) is defined as an isolate that was confirmed as VRE on
one medium but did not grow on another medium.
TABLE 3. PPV and NPV of VRE-BMX and BEAV for















24 VRE-BMX 53 6 86 2 89.8 97.7
BEAV 50 12 80 5 80.7 94.1
48 VRE-BMX 55 21 68 3 72.4 95.8
BEAV 53 18 71 5 74.7 93.4
a A true positive (TP) is defined as a blue-green or purple colony on VRE-
BMX or a gray to black colony on BEAV that was identified as VRE by VITEK
2 and confirmed by PCR.
b A false positive (FP) is defined as an isolate that exhibited typical coloration
on the respective medium but was not identified as VRE by VITEK 2 or
confirmed by PCR.
c A true negative (TN) is defined as the lack of a typically colored colony.
d A false negative (FN) is defined as an isolate that was confirmed as VRE on
one medium but did not grow on another medium.
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VRE-BMX produced a PPV of 92.7% for vancomycin-resis-
tant E. faecium (vanA or vanB) and 75.0% for vancomycin-
resistant E. faecalis (vanA or vanB) at 24 h. By comparison, the
PPV of BEAV for all VRE was 76.9% at 24 h and did not
change significantly when the incubation period was extended
to 48 h.
Growth of contaminants. Breakthrough growth of contami-
nants on each medium was assessed at 24 and 48 h to deter-
mine the efficacy of the antimicrobial agents in VRE-BMX to
suppress proliferation of normal stool flora (non-VRE). Con-
taminants were classified into two groups: (i) those that were
considered potential false positives because they produced col-
onies with any hue of blue-green or purple on VRE-BMX that
could be misinterpreted as vancomycin-resistant E. faecium or
E. faecalis, or resulted in black colonies on BEAV, and (ii)
colorless isolates. While BEAV grew 50% more contaminants
at 24 h than did VRE-BMX, extending the incubation period
to 48 h resulted in 24 and 26 cultures with breakthrough
growth, respectively, on BEAV and VRE-BMX (Fig. 2). Iso-
lates most likely to cause false-positive results on VRE-BMX
included Candida spp. and gram-negative rods. Contaminants
causing potential false-positive results on BEAV included En-
terococcus spp. other than E. faecium and E. faecalis, gram-
positive rods, and Streptococcus spp. Most breakthrough
growth on VRE-BMX consisted of lightly green-colored colo-
nies in the first quadrant of growth. However, contaminants on
BEAV were found on all quadrants and were more likely to be
Enterococcus spp. other than E. faecium and E. faecalis.
DISCUSSION
Recognizing the clinical impact of the VRE epidemic, the CDC
drafted recommendations in 1995 to assist infection control per-
sonnel and hospital epidemiologists with the rapid spread of this
organism within the hospital environment (4). Fundamental to
these recommendations were strategies to contain cases or out-
breaks of VRE and decrease the rates of transmission, including
the isolation of VRE-infected or -colonized patients. The devel-
opment of a sensitive method for detection of VRE colonization/
infection, and preferably one that is rapid and simple to perform
so as to facilitate screening of large numbers of patient samples
with prompt isolation, is central to this goal.
The identification of VRE from colonized patients can be
accomplished by screening cultures of stool or rectal swabs
with differential and/or selective media. One such medium,
BEAV, has the advantage of suppressing the normal fecal flora
and allowing for growth of organisms carrying clinically signif-
icant glycopeptide resistance genes, such as vanA or vanB.
However, the disadvantage of BEAV is that additional confir-
matory tests are required to identify isolates and confirm glyco-
peptide resistance. Performing such tests on all of the colony
morphotypes consistent with VRE can be time consuming and
labor intense. In response to this problem, a number of manu-
facturers have developed novel methods of detecting VRE colo-
nization that do not require confirmatory testing. These include
molecular techniques, such as real-time PCR, and novel culture
media.
FIG. 2. Growth of contaminants on each medium at 24 and 48 h. Contaminants are classified as potential false-positive isolates and colorless
isolates. Isolates with any hue of blue-green or purple were classified as potential false positives on VRE-BMX; isolates with a black hue on BEAV
were classified as potential false positives.
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While real-time gene amplification methods are currently
being developed for the detection of agents such as VRE, they
often add a level of cost and complexity that are not in line with
the clinical relevance of the targeted organism. Though these
methods offer the benefit of decreased turn-around time and
have been shown to be significantly more sensitive than culture
for many viruses, their utility for bacteria, especially organisms
that comprise the normal gut flora, is more nebulous. For
example, nucleic acid amplification techniques can identify
antimicrobial resistance genes in the absence of a viable or-
ganism or when the resistance determinant is carried by an
organism other than the targeted bacterium. In the latter ex-
ample, the detection of vanA or vanB carried by an organism
other than VRE in the presence of a pan-susceptible entero-
coccus could provide misleading information.
To address these issues, the ideal candidate for a VRE
screen would be selective and differential: able to differentiate
vancomycin-resistant Enterococcus faecalis from Enterococcus
faecium without the additional step of identification and resis-
tance confirmation. Further, the screen would have reasonable
sensitivity for screening purposes and specificity to limit the
need for additional testing.
The data presented in this article show that a chromogenic
medium, VRE-BMX, from bioMe´rieux provides a viable alter-
native for screening of patients for gut colonization with VRE.
This medium is able to identify and differentiate vancomycin-
resistant E. faecium from E. faecalis while inhibiting growth of
vancomycin-susceptible Enterococcus spp. Because this me-
dium reliably identifies enterococci to species level and con-
firms glycopeptide resistance, it is not necessary to pursue
additional biochemical analysis or determine antimicrobial
susceptibilities in the clinical laboratory.
In this evaluation, BEAV culture combined with PCR was
used as the “gold standard” for detection and confirmation of
VRE from fecal specimens. After incubation of the plates for
24 and 48 h, the sensitivity, specificity, PPV, and NPV were
calculated. In each of these analyses, we determined that
VRE-BMX was at least a comparable, if not a superior, alter-
native to BEAV for the detection of VRE. Since BEAV does
not identify Enterococcus to the species level and requires
additional steps to obtain these data for infection control pur-
poses, we conclude that VRE-BMX provides value-added
qualities to a VRE screening agar. Our comparison showed
that incubation of VRE-BMX beyond 24 h did not improve the
sensitivity of the medium and actually reduced the specificity
due to breakthrough growth of normal glycopeptide-resistant
flora, such as Candida species. We noted that this was primar-
ily observed in the first quadrant of the medium. When spec-
imens were inoculated onto the medium, residual stool gener-
ally remained in the first quadrant. The excess specimen likely
overwhelmed the inhibitory level of the vancomycin within the
medium. To circumvent this problem, we would recommend
first placing samples in a sterile diluent such as saline before
plating and limiting the evaluation to 24 h of incubation.
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